NZCR is proud to announce its involvement in a newly released global series by BBC StoryWorks, The Next Frontier, presented by the Biotechnology Innovation Organisation (BIO). The series explores how biotechnology is tackling some of the world’s most critical health and sustainability challenges.
NZCR’s contribution to the series centres on a groundbreaking collaboration with clinical research sponsor Novotech and Tune Therapeutics, aimed at advancing a functional cure for Hepatitis B – a chronic viral disease that affects nearly 300 million people worldwide.
The feature, filmed in New Zealand, showcases the expertise of Professor Ed Gane, NZCR’s Chief Medical Adviser and leading Principal Investigator (PI) on the project. With over 20 years of PI experience and an international reputation for his pioneering work in Hepatitis B and C – including the development of early oral therapies – Professor Gane brings an unparalleled depth of clinical insight to this global initiative.
“This research reflects what’s possible when deep therapeutic expertise is combined with a commitment to innovation and patient-focused outcomes,” said Professor Gane, who has authored more than 360 peer-reviewed publications and contributed to eight medical book chapters. “At NZCR, we believe in accelerating access to transformative therapies – not just for the few, but for the millions still waiting.”
New Zealand, where the documentary was filmed, has an estimated 100,000 people living with Hepatitis B, making it an important site for targeted research and patient recruitment. Professor Gane’s leadership has helped establish NZCR as a trusted partner in high-impact infectious disease trials across Asia-Pacific and beyond.
As featured in The Next Frontier, the collaboration between NZCR, Novotech, and Tune Therapeutics is a shining example of how regionally focused clinical trial capabilities can drive global outcomes. With access to expert investigators, patient populations, and a streamlined trial infrastructure, the initiative highlights a smarter, faster pathway for biotech and mid-sized pharma sponsors.
Tom Hickey, Director of Therapeutic Strategy at Novotech, said: “Our inclusion in this global series reflects our commitment to supporting innovators with regionally tailored clinical solutions. NZCR and Professor Gane exemplify what it means to drive real progress in the fight against Hepatitis B.”
The Next Frontier officially launched at the BIO International Convention in Boston on June 16, 2025, and is now available worldwide via BBC.com.
As NZCR continues to lead in the field of hepatitis and gene therapy research, the organisation remains dedicated to accelerating the delivery of life-changing therapies through trusted partnerships, clinical excellence, and scientific integrity.
For more information about NZCR’s capabilities in infectious disease research, contact our team or visit www.nzcr.co.nz.
